Use of aldosterone antagonists to inhibit myocardial fibrosis

A method of inhibiting aldosterone-mediated myocardial fibrosis in a patient at risk of myocardial fibrosis, comprising administering to a patient in need thereof an aldosterone antagonist which suppresses activity at aldosterone receptors in a mammalian body, wherein said aldosterone antagonist is administered in a quantity that is therapeutically effective in suppressing aldosterone-mediated myocardial fibrosis without substantially increasing sodium excretion by the body.

A method of inhibiting aldosterone-mediated deposition of pathological concentrations of collagen, comprising administering to a patient in need thereof an aldosterone antagonist which suppresses activity at aldosterone receptors in a mammalian body, wherein said aldosterone antagonist is administered in a quantity that is therapeutically effective in suppressing aldosterone-mediated deposition of pathological concentrations of collagen without substantially increasing sodium excretion by the body.

A method of inhibiting aldosterone-mediated reactive fibrosis, comprising administering to a patient in need thereof an aldosterone antagonist which suppresses activity at aldosterone receptors in a mammalian body, wherein said aldosterone antagonist is administered in a quantity that is therapeutically effective in suppressing reactive fibrosis without substantially increasing sodium excretion by the body.

A method of inhibiting aldosterone-mediated perivascular fibrosis, comprising administering to a patient in need thereof an aldosterone antagonist which suppresses activity at aldosterone receptors in a mammalian body, wherein said aldosterone antagonist is administered in a quantity that is therapeutically effective in suppressing perivascular fibrosis without substantially increasing sodium excretion by the body.